ArriVent BioPharma, Inc.
AVBP
$25.22
$0.331.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -212.06% | -0.34% | 5.99% | -25.59% | 17.82% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 138.55% | 9.93% | 13.20% | 22.40% | 95.92% |
| Change in Net Operating Assets | -266.96% | 5.25% | 65.83% | 210.13% | -130.80% |
| Cash from Operations | -321.05% | 1.18% | 14.37% | -2.46% | -24.91% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 119.13% | -- | -- | -- | -- |
| Cash from Investing | 119.13% | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12,280.00% | -89.64% | 46.28% | -99.80% | 65,034.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 12,189.09% | -89.64% | 46.28% | -99.80% | 17,662.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.29% | -1,218.84% | 15.54% | -111.21% | 1,749.44% |